dihydroergotoxine and Migraine-Disorders

Topics: Animals; Brain Diseases; Bromocriptine; Dihydroergotamine; Dihydroergotoxine; Dopamine Antagonists; Ergot Alkaloids; Ergotamine; Female; Humans; Methysergide; Migraine Disorders; Parkinson Disease; Pituitary Gland; Prolactin; Receptors, Adrenergic; Receptors, Dopamine; Uterus; Vasoconstriction

This multicenter, double-blind, clinical study was designed to compare the efficacy and safety of alpha-dihydroergocryptine and flunarizine in the prophylaxis of migraine without aura. One hundred thirty-five patients fulfilling the diagnostic criteria of the International Headache Society were enrolled at five neurologic centers. The study design included a 1-month pretreatment phase with placebo; a 6-month, double-blind, double-dummy treatment phase with alpha-dihydroergocryptine (10 mg twice daily) or flunarizine (5 mg once daily); a further 3-month follow-up phase without treatment. Efficacy was assessed using the patient's diary. Laboratory tests, vital signs, and adverse events were monitored. Analysis of covariance for repeated measures was performed on the intent-to-treat sample. Both treatments led to a significant reduction in the frequency of migraine, days with headache, and use of relief medication. Overall, 51% of those treated with alpha-dihydroergocryptine and 49% of those treated with flunarizine were responders (50% or greater reduction in attack frequency), the average percentage of reduction being 64% with alpha-dihydroergocryptine and 51% with flunarizine. There was no significant difference between the two groups in terms of incidence of adverse events; dizziness and weight gain were the most frequent observed adverse events with alpha-dihydroergocryptine and flunarizine, respectively. Based on the overall improvement in migraine parameters, alpha-dihydroergocryptine can be recommended for use in migraine prophylaxis.

Topics: Adult; Dihydroergotoxine; Double-Blind Method; Female; Flunarizine; Humans; Male; Middle Aged; Migraine Disorders; Recurrence; Treatment Outcome

Dihydroergokryptine has been evaluated in the prophylaxis of headache attacks in patients with migraine without aura. The study was controlled vs dihydroergotamine with a double-blind crossover design. After a 1-month run-in period, 30 patients were randomized into two groups and submitted to 4 months treatment with dihydroergokryptine 10 mg b.i.d. or dihydroergotamine (controlled release) 5 mg b.i.d. The treatment was repeated in crossover after 2 months washout. The clinical patients' evaluation was determined by monthly Pain Total Index recording, headache days/month and analgesic consumption. The patients were considered responsible when Pain Total Index decreased by 50% or more in 1 or more months of each treatment period; otherwise the patients were considered unresponsive. The response rate to dihydroergokryptine was 66% while 48% of cases were responsive to dihydroergotamine. The response rate to both treatments was 41%, while 26% did not respond to either treatment. Seven cases unresponsive to dihydroergotamine responded positively to dihydroergokryptine while two cases only, resistant to dihydroergokryptine, responded positively to dihydroergotamine. Three cases dropped out during treatment with dihydroergotamine due to gastric pain and nausea, while they did not show any side effects during dihydroergokryptine therapy. During treatment with dihydroergokryptine there was one case of skin rash which disappeared after drug withdrawal. In conclusion, dihydroergokryptine appears to be an effective drug for the prophylaxis of migraine attacks.

Topics: Adult; Analgesics; Dihydroergotamine; Dihydroergotoxine; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Time Factors

Topics: Acupuncture Analgesia; Adrenochrome; Adult; Dihydroergotoxine; Electroacupuncture; Female; Follow-Up Studies; Humans; Indolequinones; Male; Migraine Disorders; Prospective Studies; Randomized Controlled Trials as Topic; Serotonin Antagonists; Transcutaneous Electric Nerve Stimulation

The results of an open prospective trial on the treatment of migraine with vasobral which was conducted in 170 medical centers (27 cities) of the Russian Federation are summarized. The trial included 5475 patients treated with vasobral in dosage 2 ml (1 ml contains 1 mg of alpha-dihydroergocryptine and 10 mg of caffeine) twice a day during 2 months. Assessment criteria of treatment efficacy were frequency and duration of migraine seizures, pain syndrome severity, presence of concomitant syndromes, general state and working capacity of patients and side-effects. Vasobral was effective and safe medication for the prevention of migraine. Its preventive effect is due to the decrease of frequency and duration of migraine seizures, pain severity and to the overall improvement of patient's state. Vasobral can be recommended to many migraine patients, in particular to those in the young age and with short disease duration.

Topics: Adolescent; Adult; Aged; Caffeine; Dihydroergotoxine; Drug Combinations; Female; Humans; Male; Middle Aged; Migraine Disorders; Prospective Studies; Treatment Outcome; Young Adult

Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Dihydroergotoxine; Drug Evaluation; Female; Humans; Hypertension; Male; Middle Aged; Migraine Disorders; Vascular Diseases

Topics: Anti-Anxiety Agents; Benzodiazepines; Cerebrovascular Disorders; Cluster Headache; Delayed-Action Preparations; Dihydroergotamine; Dihydroergotoxine; Headache; Humans; Methysergide; Migraine Disorders; Vascular Headaches

Topics: Dihydroergotoxine; Ergot Alkaloids; Ergotamine; Hemangioma; Humans; Migraine Disorders

Topics: Alkaloids; Cardiovascular Agents; Dihydroergotoxine; Ergot Alkaloids; Humans; Migraine Disorders; Migraine with Aura

Topics: Cardiovascular Agents; Dihydroergocornine; Dihydroergocristine; Dihydroergocryptine; Dihydroergotoxine; Ergot Alkaloids; Migraine Disorders; Oxytocics; Safe Sex